Stocks Funds Screener Sectors Watchlists

IGMS - IGM Biosciences Inc Stock Price, Fair Value and News

$1.27

Market Closed as of 15 Aug 2025, 04:00 pm ET

IGMS Stock Valuation Analysis

Valuation

Max Portfolio %

IGMS Price Action

IGMS RSI Chart

IGMS Stock Valuation Analysis

Valuation

Max Portfolio %

IGMS Valuation

IGMS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IGMS Fundamentals

IGMS Revenue

IGMS Earnings

IGMS Profitability

IGMS Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	2.1M	2.9M	2.9M	0
2023	1.3M	1.6M	1.9M	2.1M
2022	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About IGM Biosciences Inc

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

CEO	Mr. Fred M. Schwarzer J.D.
WEBSITE	https://igmbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	289